Terns Pharmaceuticals Inc (TERN)
5.905
-0.24
(-3.83%)
USD |
NASDAQ |
May 17, 16:00
5.905
0.00 (0.00%)
After-Hours: 20:00
Terns Pharmaceuticals Research and Development Expense (Annual): 63.50M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 63.50M |
| December 31, 2022 | 39.62M |
| December 31, 2021 | 31.31M |
| Date | Value |
|---|---|
| December 31, 2020 | 28.03M |
| December 31, 2019 | 61.53M |
| December 31, 2018 | 14.55M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
28.03M
Minimum
2020
63.50M
Maximum
2023
44.80M
Average
39.62M
Median
2022
Research and Development Expense (Annual) Benchmarks
| Viking Therapeutics Inc | 63.81M |
| Eli Lilly and Co | 9.313B |
| Pfizer Inc | 10.68B |
| Amgen Inc | 4.784B |
| Madrigal Pharmaceuticals Inc | 272.35M |